Health-Related Quality-of-Life Outcomes With TKI Therapy in Newly Diagnosed CML
Posted: Thursday, October 31, 2019
Patients with chronic myeloid leukemia (CML) who are treated with first-line dasatinib reported better health-related quality of life than those treated with first-line imatinib, according to the results of a multicenter case-control study published in Leukemia. “Our findings provide novel comparative [health-related quality-of-life] data that extend knowledge on the safety and efficacy of these two [tyrosine kinase inhibitors] and may help to facilitate first-line treatment decisions,” stated Fabio Efficace, PhD, of the Italian Group for Adult Hematologic Diseases, Rome, and colleagues.
Health-related quality of life was assessed in 323 newly diagnosed patients with CML receiving imatinib (n = 223) and dasatinib (n = 100). The European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire for CML (EORTC QLQ-CML24) was the primary scale for the comparative analysis.
Patients treated with dasatinib reported significantly higher disease-specific health-related quality-of-life outcomes in impact on daily life (P = .002), satisfaction with social life (P = .001), and symptom burden (P = .001). In patients 60 years of age and older, however, the differences favoring dasatinib were negligible across several cancer generic and disease-specific health-related quality-of-life categories.
Disclosure: For full disclosures of study authors, visit nature.com.